Laurence Harris

Partner
Full contact info

Protecting my clients; arguing their position passionately, and achieving the best commercial result I can is what I come to work to do.

Passions

My family

Travelling to interesting places

Experience

Redx Pharma to Merge With Jounce Therapeutics

March 6, 2023

Cooley advised Redx Pharma, a UK clinical-stage biotechnology company, on its all share merger with Jounce Therapeutics, a US clinical-stage immunotherapy company, in a $425 million and contingent value right transaction.

Related contacts

Michal Berkner
Partner, London
Claire Keast-Butler
Partner, London
Russell Anderson
Associate, London
Rita Sobral
Associate, London
Natasha Kaye
Partner, London
Nicola Squire
Partner, London
Aaron Pomeroy
Partner, Colorado
Megan Browdie
Partner, Washington DC
Caroline Hobson
Partner, London
Paula Holland
Partner, London
David Wilson
Partner, London
Josh Kaufman
Partner, New York
Laurence Harris
Partner, London
Chris Stack
Partner, London
Jeff Goldman
Special Counsel, Palo Alto
Sharon Connaughton
Special Counsel, Washington DC
Stacey A. Bradford
Special Counsel, Washington DC
Charlotte Irvine
Associate, London
Vlad Herta
Associate, London
Bethan Chalmers
Associate, London
Dov Fiskus
Associate, New York
Amanda Griggs
Associate, New York
Anna Caro
Associate, London
Rick Jantz
Associate, Los Angeles Santa Monica
Dionne A. Thomas
Associate, San Diego

Cooley Secures Transatlantic Win for IQVIA

February 11, 2022

A transatlantic Cooley team successfully represented biopharmaceutical company IQVIA in a breach of contract and unfair business practices case in which the High Court of Justice of England and Wales rendered a lengthy and detailed verdict in favor of IQVIA on all claims and counterclaims. Partners Mike Klisch, Henry Stewart, Laurence Harris and Bob Cahill led the Cooley team advising IQVIA.

Read more

Related contacts

Mike Klisch
Partner, Washington DC
Laurence Harris
Partner, London
Robert Cahill
Partner, Reston
Henry Stewart
Partner, London

Related Practices & Industries

Bavarian Nordic Acquires Two Commercial Vaccines from GlaxoSmithKline for €796 Million

October 7, 2019

Cooley advised Bavarian Nordic, an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases, on its agreement to acquire the manufacturing and global rights to two commercial vaccines – Rabipur/RabAvert and Encepur – from GlaxoSmithKline, for €796 million. Partners Nicola Maguire and John Wilkinson led the Cooley team.

Related contacts

Nicola Maguire
Partner, London
John Wilkinson
Partner, London
Sharon Connaughton
Special Counsel, Washington DC
Stella Sarma
Special Counsel, Brussels
Joe Sandys
Associate, London
Howard Morse
Partner, Washington DC
Natasha Kaye
Partner, London
Natasha Leskovsek
Of Counsel, Washington DC
Laurence Harris
Partner, London
Chris Stack
Partner, London
David Wilson
Partner, London
Margie Murphy
Paralegal Specialist, New York

Related Practices & Industries

Acting for Governments on major asset recovery programmes, including bringing cases to recover substantial damages, land and other assets around the world

Advising a US public company on a dispute arising out of the termination of an international licensing and collaboration agreement of the development of a drug including a Phase 2 trial. The case involved obtaining a mandatory injunction in support of arbitration proceedings and obtaining a substantial judgment and damages for the client.

Related contacts

Laurence Harris
Partner, London

Rankings & accolades

The Legal 500 UK: Dispute Resolution (2022)

The Legal 500 UK: Commercial Litigation - Premium (2022)

The Legal 500 UK: Crime, fraud and licensing (2022)

 

Memberships & affiliations

The Access to Justice Foundation - Chairman of the Board of Trustees